YouTube Facebook LinkedIn Google+ Twitter Xingrss  

January-February Briefs


Cancer Genomes Mapped

Scientists at the Wellcome Trust Sanger Institute have sequenced lung cancer (on the SOLiD system) and melanoma (on Illumina’s system). The two studies were published in Nature in December. Researchers discovered 33,000 DNA errors in melanoma, most caused by sun exposure and 23,000 errors in lung cancer, most due to cigarette smoke—one for every 15 cigarettes. Wellcome Trust researchers predict that this will be the beginning of thinking about cancer in a very different way.

Pharma IPO

Aveo Pharmaceuticals signaled a brighter 2010 for the pharma industry by filing for an initial public offering in mid-December. The cancer therapeutics firm, originally known as GenPath and with a start-studded advisory board that reads like a Who’s Who of the oncology community, is a former Bio•IT World “company to watch.”

HP Supports Lilly

HP Enterprise Services signed a seven-year infrastructure agreement with Eli Lilly and Company to provide the pharma with a flexible and scalable foundation to support Lilly’s technology needs and improve its ability to collaborate with external partners. Under the terms of the agreement, HP will manage Lilly’s employee workplace computing and messaging environment across its global operations, including service desk and site support services for more than 60,000 employee desktops.

Third Gen Sequencing

The Chinese Academy of Sciences and Inspur Group have reportedly started a joint project to develop a third-generation genome sequencing instrument. The instrument is expected to sequence a person’s genome in an hour at the cost of $1000.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.